20-F: ALR Technologies SG Ltd. Faces Going Concern Doubts Amidst Recurring Losses

ALR Technologies SG Ltd. reports recurring losses and raises substantial doubt about its ability to continue as a going concern, despite efforts to develop and commercialize its Diabetes Solution and GluCurve products.

Summary

• ALR Technologies SG Ltd. faces substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional capital.
• The company had an accumulated deficit of $135,985,914 as of December 31, 2024, and net losses of $15,877,514 for the year ended December 31, 2024.
• To continue operations, the company must develop and deploy its products, increase sales, decrease expenses, generate cash from operations, or raise additional funds.
• The company's success depends on securing relationships with third-party distributors and distinguishing its products from competitors.
• The company faces competition from companies with greater resources and must navigate a complex regulatory environment.
• The company's ordinary shares are quoted on the OTC Pink market, which has low trading volumes and reduced liquidity.
• The company's Chairman and CEO, Sidney Chan, and his affiliates own in excess of 60% of the company's outstanding ordinary shares.
• The company is organized under the laws of Singapore, which may make it more difficult for shareholders to protect their interests.
• The company may be classified as a Passive Foreign Investment Company, which could result in adverse U.S. federal income tax consequences to U.S. Holders of its ordinary shares.

Sentiment

Score: 3

Explanation: The document paints a concerning picture of the company's financial health, with recurring losses, a significant working capital deficiency, and doubts about its ability to continue as a going concern. While there are some positive aspects, such as the development of innovative products and strategic partnerships, the overall sentiment is negative due to the company's financial instability.

Positives

• The company has developed the Diabetes Solution and GluCurve products, which have received FDA clearance and are HIPAA compliant.
• The company has a patent-pending Predictive A1C algorithm and an FDA-cleared Insulin Dosing Adjustment program.
• The company is actively seeking to commence revenue-generating activities for its Diabetes Solution product.
• The company has entered into a co-branded products distribution agreement with Covetrus, Inc. for its GluCurve Pet CGM product.
• The company has completed a 24-week study led by Singapore General Hospital, which validated the value that ALRT Diabetes Solution may potentially bring to patients and health care providers.

Negatives

• The company has a history of operating losses and a substantial accumulated deficit.
• The company faces substantial doubt about its ability to continue as a going concern.
• The company's third-party distributor has generated limited sales to date.
• The company's inability to distinguish its Diabetes Solution and GluCurve products from other diabetes treatment compliance devices or solutions could limit market acceptance.
• The company has experienced long sales cycles as healthcare professionals have been slow to adopt new technologies.
• The company could face product liability claims, which could be costly and harm its reputation.
• The company's ordinary shares are classified as penny stocks and are covered by Section 15(g) of the Exchange Act, which imposes additional sales practice requirements on broker-dealers who sell the company's securities.
• The company's share price has been, and could continue to be, volatile.

Risks

• The company's recurring losses and need for additional funding raise substantial doubt about its ability to continue as a going concern.
• The company's reliance on third-party distributors and the potential failure of these relationships pose a risk to revenue generation.
• The company's inability to distinguish its products from competitors and the slow adoption of new technologies by healthcare professionals could limit market acceptance.
• The company faces competition from companies with greater resources and must navigate a complex regulatory environment.
• The company's ordinary shares trade on the OTC Pink market, which has low trading volumes and reduced liquidity.
• The company's CEO and his affiliates hold a majority stake, which could lead to conflicts of interest.
• The company is subject to product liability claims and breaches of its information technology systems.
• The company may be classified as a Passive Foreign Investment Company, potentially impacting U.S. shareholders.
• The company may lose its foreign private issuer status, which could result in significant additional costs and expenses.

Future Outlook

The company plans to become a commercially viable enterprise through the sale of GluCurve Pet CGM products and the subsequent launch of the Diabetes Solution product. The Company needs to identify and source suitable CGM hardware from third parties to commence selling the second generation GluCurve Pet CGM product. The Company expects to identify CGM systems during 2025 for which it can subsequently initiate a clinical trial and prepare for a subsequent clearance from regulatory authorities to sell in key target countries for roll out.

Management Comments

• Management is evaluating alternatives to penetrate both existing and new marketplaces in order to generate cash flows.
• Management believes our business plan will give us the best opportunity to achieve commercial feasibility.

Industry Context

The diabetes management market is highly competitive and fragmented, with rapid technological changes and the entry of new competitors. The company faces competition from companies with greater resources and must navigate a complex regulatory environment.

Comparison to Industry Standards

• The document mentions competitors such as Livongo, Glooko, WellDoc, Medtronic, iGlucose, and Microsoft HealthVault in the human health segment.
• In the animal health segment, AlphaTRAK is mentioned as the largest and most established product for diabetes care.
• The document positions ALR Technologies' products as offering a more comprehensive compliance system with potential cost efficiencies compared to competitors.
• However, it lacks specific details on how ALR Technologies' results compare to industry benchmarks in terms of revenue, market share, or profitability.

Legal Proceedings

• The company has had three judgments against it relating to overdue promissory notes and accrued interest, and a fourth creditor has demanded repayment of an overdue promissory note and accrued interest.
• On December 22, 2020, a default judgment was entered against the company in regard to one of the above noted judgments totaling $552,000.
• On January 17, 2024, another default judgment was entered against the company in regard to one of the above noted judgments totaling $255,000.

Related Party Transactions

• The company has significant related party transactions, including interest on promissory notes payable, lines of credit and loans payable to related parties, management compensation, and compensation paid to a relative of a director.

Stakeholder Impact

• Shareholders could lose all or part of their investment in the company's ordinary shares if the company becomes unable to continue as a going concern.
• Employees may be affected by potential layoffs or salary reductions if the company is unable to improve its financial situation.
• Customers may be affected by potential disruptions in the supply of the company's products and services.
• Suppliers and creditors may be affected by potential delays or defaults in payments.

Next Steps

• The company needs to identify and source suitable CGM hardware from third parties to commence selling the second generation GluCurve Pet CGM product.
• The company will seek to obtain creditors' consents to delay repayment of its loans until it is able to replace these financings with funds generated by operations, replacement debt, or from equity financings through private placements.
• The company will continue to monitor and evaluate the effectiveness of its internal controls and procedures and its internal controls over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

Key Dates

Keywords

Diabetes Solution, GluCurve, going concern, financial results, losses, capital, distributors, regulatory, OTC Pink, penny stock, Singapore